Axio BioPharma Launches New Protein Manufacturing Capabilities

• Axio BioPharma is now accepting recombinant protein manufacturing projects at its Madison facility, offering small-scale research-grade production.

• The company plans to expand its capabilities with GMP mammalian manufacturing by 2028.

Axio BioPharma has announced that it is now accepting recombinant protein manufacturing projects, marking a step forward in its mission to support the biopharmaceutical industry. Operating from Forward BIOLABS in Madison, Wisconsin, the company specializes in the small-scale production of monoclonal antibodies (mAbs) and mammalian-expressed proteins, catering to research and development programs.

“With our innovative manufacturing approach, we are committed to accelerating the development of life-saving therapies,” said Justin Byers, Founder and CEO of Axio BioPharma.

The company focuses on research-grade production, with scales ranging from 50 mL to 2 L, and supports clients with tailored solutions to meet their specific project needs. Looking ahead, Axio BioPharma has announced plans to introduce GMP mammalian manufacturing services by early 2028, a move that will enable the company to support its clients from early-stage research through to clinical manufacturing.

Byers added: “Our upcoming GMP services will allow us to provide even more comprehensive support to our clients. We understand the challenges in bringing new therapies to market, and we’re here to make that process faster and more efficient. Our upcoming GMP services will allow us to provide even more comprehensive support to our clients.”